CUMYL-CBMINACA
From Wikipedia, the free encyclopedia
Chemical compound
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
ChemSpider | |
Chemical and physical data | |
Formula | C22H25N3O |
Molar mass | 347.462 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug,[1] first being identified in Germany in February 2020.[2] It is illegal in Finland.[3]
See also[edit]
References[edit]
- ^ Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, et al. (August 2021). "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis. 13 (8): 1499–1515. doi:10.1002/dta.3038. PMID 33788409.
- ^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
- ^ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market]. Finlex (in Finnish). Finnish Ministry of Justice.
Receptor (ligands) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||
Enzyme (modulators) |
| ||||||||||||
Others |
| ||||||||||||
|
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- CS1 Finnish-language sources (fi)
- Articles with short description
- Short description matches Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- All stub articles